Skip to main content
Sandoz Group AG logo

Sandoz Group AG — Investor Relations & Filings

Ticker · SDZ ISIN · CH1243598427 LEI · 5493000JWK6XWFEUD320 SW Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CH Switzerland
Listing SW SDZ

About Sandoz Group AG

https://www.sandoz.com/

Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.

Recent filings

Filing Released Lang Actions
Sandoz confirms European Commission approval for biosimilars Bysumlog (insulin lispro) and Dazparda (insulin aspart), strengthening position in diabetes
Regulatory Filings Classification · 85% confidence The document is a corporate media release announcing European Commission approval of new biosimilar products. It contains no financial statements, voting results, management changes, or report attachments. It is not an earnings release or interim/annual report but a general regulatory announcement of product approvals. As such it falls under the fallback category for miscellaneous regulatory filings.
2026-05-15 English
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Regulatory Filings Classification · 80% confidence The document is a media release announcing European Commission regulatory approvals for two biosimilar drugs. It is not an annual or interim financial report, earnings release, capital markets update, management change announcement, or detailed investor presentation. It is a public compliance/regulatory announcement. Under the classification schema, general regulatory announcements and press releases that do not fit other specific categories should be classified as Regulatory Filings (RNS).
2026-05-15 English
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
Earnings Release Classification · 93% confidence The document is a media release presenting Sandoz’s first-quarter financial performance (Q1 2026), including net‐sales tables, business highlights, and full‐year guidance confirmation. It is clearly the initial announcement of quarterly results rather than a full interim report. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-29 English
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
Earnings Release Classification · 90% confidence The document is an ad hoc announcement pursuant to Art. 53 of the Swiss Exchange Listing Rules, presenting Sandoz’s net‐sales performance for Q1 2026, including key highlights, segment/regional breakdowns, strategic updates, and confirmation of full‐year guidance. It is an initial quarter‐end financial results announcement rather than a full interim report or presentation. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-29 English
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets
Regulatory Filings Classification · 60% confidence The document is a corporate media release announcing a strategic supply agreement with the Rwandan government. It is not a financial report, earnings release, management change, M&A announcement, dividend notice, or any other specific filing type. It does not represent a regulatory or compliance submission under a formal form but rather a general press announcement. As such, it falls into the fallback category for miscellaneous regulatory announcements.
2026-04-15 English
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets
Regulatory Filings Classification · 85% confidence The document is a media/press release announcing a strategic supply agreement with the Rwandan government. It contains no financial results, no shareholder vote details, no management changes, no regulatory report attached, and no detailed financial schedules. It is a general corporate announcement, which falls under the fallback category “Regulatory Filings” (RNS).
2026-04-15 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.